HIV and AIDS have been part of the world’s consciousness for 40 years. Since the beginning of the pandemic in 1981, 77.3 million people have contracted HIV and 35.4 million have died of AIDS-related illnesses. Today, more than a million Americans still have the virus. Being diagnosed with HIV was once a death sentence, however, with the advancement of various technologies and accumulated experience, some treatments are proved to be effective to provide relief, among which convertibleCAR-T Cell, a highly adaptable killing platform, has great potential.
In order to advance the discovery of HIV cure and the exploration of CAR-T therapy, Creative Biolabs has invited Dr. Eytan Herzig to share some profound insights on the principles and opportunities of innovative convertibleCAR-T platform.
Basic information of the Webinar:
Time: 3:00 p.m. EDT/12:00 p.m. PDT (May 7th, 2020)
1. The potential approach to achieve a functional HIV cure
2. The process of convertibleCAR-T’s detecting and eliminating HIV infected cells
3. The performance of the convertibleCAR-T cells ex vivo and in vivo
4. ConvertibleCAR-T cells’ advantages over conventional CAR-T cells
Dr. Eytan Herzig is a Staff Research Scientist in the Gladstone Center for HIV Cure Research at the University of California, San Francisco, where he leads the use of new technologies to fight HIV. He published a paper entitled Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform on Cell as the first author on 31 October 2019, introducing this potential treatment of HIV.
Dr. Eytan Herzig and his team have designed a universal CAR-T cell platform based on Endogenous cytotoxic T-lymphocytes (CTLs) engineered to bind a variety of broadly neutralizing anti-HIV antibodies. According to their research, this platform, convertibleCAR-T cells, effectively kills HIV-infected CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies within 48 h. They also mentioned that the modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.
Click here to register now if you are interested in this topic. Creative Biolabs, with Dr. Eytan Herzig, gives warm welcomes to all participants and will be delighted to answer any related questions during the webinar.
Further information can be reached at https://www.creative-biolabs.com/car-t.
About Creative Biolabs
As a global company, Creative Biolabs has talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs is the established leading expert in TCR and CAR T&NK cell immune therapy development, offering the one-stop custom services that cover the entire new drug development pipeline.